Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?
Treatment discontinuation is considered one of the main goals of therapy for patients with chronic myeloid leukemia. Several criteria are felt to be necessary to consider discontinuation, while others may predict a better chance of achieving treatment-free remission. Criteria for discontinuation in...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2020-10-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/10041 |